The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer

European Journal of Oncology Nursing

Volumn 12, Issue 3, 2008, Pages 233-243

  Pennery, Emma ^a  

^a Breast Cancer Care   (United Kingdom)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Distant metastases; Recurrence risk; Tamoxifen; Treatment options

Indexed keywords

ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; NITRILE; TAMOXIFEN; TRIAZOLE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HUMAN; MORTALITY; NURSE; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; PATIENT EDUCATION; PATIENT SELECTION; POSTMENOPAUSE; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; NURSE CLINICIANS; NURSE PRACTITIONERS; NURSE'S ROLE; ONCOLOGIC NURSING; PATIENT EDUCATION AS TOPIC; PATIENT SELECTION; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 46149125507     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2008.01.007     Document Type: Article

References (65)

1. Barghout V., and Dias R. Breast cancer in the US, UK, France, and Germany: whom do patients see and how do they get medical information?. European Journal of Cancer Supplements 3 (2005) 104 abstract 372
2. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., Sahmoud T., and ATAC Trialists' Group. Anastrozole alone or in combination with TAM versus TAM alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139 Erratum in: Lancet 2002, 360, 1520
3. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Annals of Oncology 16 3 (2005) 481-488
4. Carter B. Long-term survivors of breast cancer: a qualitative descriptive study. Cancer Nursing 16 5 (1993) 354-361
5. Choueiri T.K., Alemany C.A., Abou-Jawde R.M., and Budd G.T. Role of aromatase inhibitors in the treatment of breast cancer. Clinical Therapeutics 26 8 (2004) 1199-1214
6. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Colleoni M., Lang I., Del Mastro L., Smith I., Chirgwin J., Nogaret J.M., Pienkowski T., Wardley A., Jakobsen E.H., Price K.N., and Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 25 5 (2007) 486-492
7. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., Jones S.E., Alvarez I., Bertelli G., Ortmann O., Coates A.S., Bajetta E., Dodwell D., Coleman R.E., Fallowfield L.J., Mickiewicz E., Andersen J., Lonning P.E., Cocconi G., Stewart A., Stuart N., Snowdon C.F., Carpentieri M., Massimini G., Bliss J.M., and Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 11 (2004) 1081-1092 Erratum in: New England Journal of Medicine 2004, 351, 2461
8. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman F.E., Jones S.E., Jassem J., Van de Velde C.J., Delozier T., Alvarez I., Del Mastro L., Ortmann O., Diedrich K., Coates A.S., Bajetta E., Holmberg S.B., Dodwell D., Mickiewicz E., Anderson J., Lonning P.E., Cocconi G., Forbes J., Castiglione M., Stuart N., Stewart A., Fallowfield L.J., Bertelli G., Hall E., Bogle R.G., Carpentieri M., Colajori E., Subar M., Ireland E., Bliss J.M., and on behalf of the Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 9561 (2007) 559-570 Erratum in: Lancet 2007, 369 (9565), 906
9. Cuzick J., Wale C., and on behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years' treatment. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S24 abstract 104
10. de Bock G., Bonnema J., Zwaan R., van de Velde C., Kievit J., and Stiggelbout A. Patient's needs and preferences in routine follow-up after treatment for breast cancer. British Journal of Cancer 90 6 (2004) 1144-1150
11. De Boer Sr. R., Burris H.A., Monnier A., Mouridsen H., O'Shaughnessy J.A., McIntyre K., Pritchard K.I., Smith I., Yardley D., and on behalf of the H2H Trial Steering Committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Journal of Clinical Oncology 24 18s (2006) 582s abstract 10672
12. Degner L.F., Kristjanson L.J., Bowman D., Sloan J.A., Carriere K.C., O'Neil J., Bilodeau B., Watson P., and Mueller B. Information needs and decisional preferences in women with breast cancer. Journal of American Medical Association 277 18 (1997) 1485-1491
13. Degner L., Hack T., O'Neil J., and Kristjanson L. A new approach to eliciting meaning in the context of breast cancer. Cancer Nursing 26 3 (2003) 169-178
14. Delozier T., Spielmann M., Janvier M., Fourquet A., Veyret C., Weber B., Mauriac L., Petit T., and Kerbrat P. Optimal duration of adjuvant tamoxifen (TAM) in early breast cancer (EBC): ten year results of a randomized trial (TAM-01) of the FNCLCC Breast Group. Breast Cancer Research and Treatment 94 Suppl. 1 (2005) S10 abstract 14
15. Duffy S., and on behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years' follow-up. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S190 abstract 4055
16. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 (1998) 1451-1467
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
18. Fallowfield L., Ford S., and Lewis S. No news is not good news: information preferences of patients with cancer. Psychooncology 4 3 (1995) 197-202
19. Fan P., Wang J., Santen R.J., and Yue W. Long-term treatment with tamoxifen facilitates translocation of oestrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Research 67 3 (2007) 1352-1360
20. Fellowes D., Fallowfield L.J., Saunders C.M., and Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments?. Breast Cancer Research and Treatment 66 1 (2001) 73-81
21. Ferrans C. Quality of life through the eyes of survivors of breast cancer. Oncology Nursing Forum 21 10 (1994) 1645-1651
22. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., Bevers T.B., Kavanah M.T., Atkins J.N., Margolese R.G., Runowicz C.D., James J.M., Ford L.G., and Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 22 (1998) 1371-1388
23. Fisher B., Dignam J., Bryant J., and Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute 93 9 (2001) 684-690
24. Francis, P., Fleming. G., Nasi, M.L., Pagani, O., Perez, E., Walley. B., for the International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and North American Breast Intergroup, 2003. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: the SOFT, TEXT, and PERCHE trials. In: Proceedings of the 8th International Conference: Primary Therapy of Early Breast Cancer, St Gallen, Switzerland, 12-15 March 2003, abstract 104.
25. Gathering Information on Adjuvant Endocrine TherApy (GAEA) press release, 2006. Available from: 〈http://www.gaeainitiative.eu/〉 (accessed 16.05.07).
26. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J., and Panel Members. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of Oncology 16 10 (2005) 1569-1583
27. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., and Pater J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. Journal of the National Cancer Institute 97 17 (2005) 1262-1271
28. Graydon J. Women with breast cancer: their quality of life following a course of radiotherapy. Journal of Advanced Nursing 19 4 (1994) 617-622
29. Houghton J., and on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC (Arimidex, TAM, Alone or in Combination) trial. Journal of Clinical Oncology 23 16S (2005) 24S abstract 582
30. Houghton J., on behalf of the ATAC ('Arimidex', Tamoxifen, and Alone or in Combination) Trialists' Group. Initial adjuvant therapy with anastrozole (a) reduces rates of early breast cancer Recurrence and adverse events compared with Tamoxifen (t). Annals of Oncology 17 Suppl. 9 (2006) ix94 abstract 243PD
31. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., Hoctin-Boes G., Houghton J., Locker G.Y., Tobias J.S., and ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 9453 (2005) 60-62
32. Ingle J., Tu D., Shepherd L., Palmer M., Pater J., and Goss P. NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. Journal of Clinical Oncology 24 18S (2006) 15s, 549
33. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., Hilfrich J., Kwasny W., Menzel C., Samonigg H., Seifert M., Gademann G., Kaufmann M., Wolfgang J., and ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005) 455-462
34. Jakesz R., Gnant N., Greil R., Tausch C., Samonigg H., Kwasny W., Kubista E., Stierer M., Luschin G., and Mittlboeck M. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year analysis of ABCSG Trial 8. Breast Cancer Research and Treatment 94 Suppl. 1 (2005) S10 abstract 13
35. Jenkins V., Fallowfield L., and Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. British Journal of Cancer 84 1 (2001) 48-51
36. Kennecke H.F., Olivotto I.A., Speers C., Norris B., Chia S.K., Bryce C., and Gelmon K.A. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Annals of Oncology 18 1 (2007) 45-51
37. Lamerato L., Havstad S., Gandhi S., Jones D., and Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. Journal of Clinical Oncology 25 16S (2005) 62s abstract 738
38. Laurent C. No one told me I had a choice. Cancer World Magazine 17 (2007) 54-58. http://www.cancerworld.org/CancerWorld/getStaticModFile.aspx?id=1613 Available from: 〈http://www.cancerworld.org/CancerWorld/getStaticModFile.aspx?id=16 13〉 [accessed 16.05.07]
39. Lê M.G., Arriagada R., Spielmann M., Guinebretière J.M., and Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 94 11 (2002) 2813-2820
40. Letrozole (Femara) Package Insert, 2005. Novartis Pharmaceuticals Corporation, East Hanover, NJ.
41. Lipton A., Leitzel K., Ali S.M., Demers L., Harvey H.A., Chaudri-Ross H.A., Evans D., Lang R., Hackl W., Hamer P., and Carney W. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104 2 (2005) 257-263
42. Mann B.S., Johnson J.R., Kelly R., Sridhara R., Williams G., and Pazdur R. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clinical Cancer Research 11 16 (2005) 5671-5677
43. Mansell J., Monypenny I.J., Skene A.I., Abram P., Gattuso J., Abdel-Rahman A., Wilson C.R., Angerson W.J., and Doughty J.C. Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Research and Treatment 100 Suppl. 1 (2006) S110 abstract 2091
44. Mauriac L., Keshaviah A., Debled M., Mouridsen H., Forbes J., Thurlimann B., Paridaens R., Monnier A., Lang I., Wardley A., Nogaret J.M., Gelber R., Castiglione-Gertsch M., Price K., Coates A., Smith I., Viale G., Rabaglio M., Zabaznyi N., and Goldhirsch A. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Annals of Oncology 18 5 (2007) 859-867
45. McArthur H.L., Olivotto I., Gelmon K.A., Speers C.H., Chia S., Ellard S., and Kennecke H.F. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on TAM. Breast Cancer Research and Treatment 94 Suppl. 1 (2005) S124 abstract 3001
46. Monroe K.R., Murphy S.P., Kolonel L.N., and Pike M.C. Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: the Multiethnic Cohort Study. British Journal of Cancer 97 3 (2007) 440-445
47. Monteiro Grillo I., Jorge M., Marques Vidal P., Ortiz M., and Ravasco P. The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma. Clinical Oncology (Royal College of Radiologists (Great Britain)) 17 2 (2005) 111-117
48. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., and Morales A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. American Journal of Clinical Pathology 123 1 (2005) 21-27
49. National Cancer Institute. Clinical Announcement: Adjuvant Therapy of Breast Cancer-Tamoxifen Update (1995), National Institutes of Health, Bethesda, MD
50. Naylor C.D., Chen E., and Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?. Annals of Internal Medicine 117 11 (1992) 916-921
51. Northouse L. Mastectomy patients and the fear of cancer recurrence. Cancer Nursing 4 3 (1981) 213-220
52. Palsson M.-B., and Norberg A. Breast cancer patients' experiences of nursing care with the focus on emotional support: the implementation of a nursing intervention. Journal of Advanced Nursing 21 2 (1995) 277-285
53. Parker B., and Sukumar S. Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biology and Therapy 2 1 (2003) 14-21
54. Rakovitch E., Pignol J.P., Chartier C., Ezer M., Verma S., Dranitsaris G., and Clemons M. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Research and Treatment 90 2 (2005) 139-148
55. Robert N.J., Goss P.E., Ingle J.N., Tu D., Shepherd L., Palmer M., and Pater J. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. Journal of Clinical Oncology 24 18S (2006) 15s abstract 550
56. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology 14 10 (1996) 2738-2746
57. Shou J., Massarweh S., Osborne C.K., Wakeling A.E., Ali S., Weiss H., and Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute 96 12 (2004) 926-935
58. Thorne C. Clinical management of arthralgia and bone health in women undergoing adjuvant aromatase inhibitor therapy. Current Opinion in Oncology 19 Suppl. 1 (2007) S19-S28
59. Thürlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., Paridaens R., Castiglione-Gertsch M., Gelber R.D., Rabaglio M., Smith I., Wardley A., Price K.N., Goldhirsch A., and Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and TAM in postmenopausal women with early breast cancer. New England Journal of Medicine 353 26 (2005) 2747-2757
60. Tyczynski J.E., Plesko I., Aareleid T., Primic-Zakelj M., Dalmas M., Kurtinaitis J., Stengrevics A., and Parkin D.M. Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly. International Journal of Cancer 112 6 (2004) 1056-1064
61. van Gestel Y.R., Voogd A.C., Vingerhoets A.J., Mols F., Nieuwenhuijzen G.A., van Driel O.J., van Berlo C.L., and van de Poll-Franse L.V. A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. European Journal of Cancer 43 3 (2007) 549-556
62. Viale P.H. Aromatase inhibitor agents in breast cancer: evolving practices in hormonal therapy treatment. Oncology Nursing Forum 32 2 (2005) 343-353
63. Wengstrom Y., Aapro M., Leto di Priolo S., Cannon H., and Georgiou V. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 16 (2007) 462-468
64. Whelan T.J., Goss P.E., Ingle J.N., Pater J.L., Tu D., Pritchard K., Liu S., Shepherd L.E., Palmer M., Robert N.J., Martino S., and Muss H.B. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology 23 28 (2005) 6931-6940
65. Whiteman M.K., Staropoli C.A., Langenberg P.W., McCarter R.J., Kjerulff K.H., and Flaws J.A. Smoking, body mass, and hot flashes in midlife women. Obstetrics and Gynecology 101 2 (2003) 264-272